Diagnosis with acceptable antimicrobial therapy saves both sight and life. This study documents circumstances of mucormycosis and their managementfromauniqueperspective. Mostofthestudiesdoneonmucormycosisareretrospective. Duetoincreaseinnumberofcases,diverseriskfactors,and inclusion of immunocompetent and immunocompromised sufferers, this study was undertaken to identify demography and linked danger elements, population at danger, presenting signs and symptoms, internet site of involvement, and outcome of therapy.MethodsThisisaprospectivecohortstudydoneonprovenmucormycosis patientswhopresentedatourtertiarycarehospitalfromMarch toMay2021(patientsenrolledtill30May2021).Thewritten informedconsentwasobtainedfromallthestudysubjects.That is an open access journal, and articles are distributed below the terms of the Inventive Commons AttributionNonCommercialShareAlike four.0 License, which makes it possible for other individuals to remix, tweak, and build upon the perform noncommercially, as long as appropriate credit is offered and also the new creations are licensed beneath the identical terms. For reprints speak to: WKHLRPMedknow_reprints@wolterskluwer Cite this article as: Walia S, Bhaisare V, Rawat P, Kori N, Sharma M, Gupta N, et al. COVID-19-associated mucormycosis: Preliminary report from a tertiary eye care centre. Indian J Ophthalmol 2021;69:3685-9.2021 Indian Journal of Ophthalmology | Published by Wolters Kluwer – MedknowIndianJournalofOphthalmologyVolume69IssueAllthecasespresentingwithcomplaintsoffacialpainand swelling, toothache, nasal blockage, breathlessness, fever, lethargy, ptosis, ophthalmoplegia, sudden loss of vision, black eschar more than palate/lid/conjunctiva/cornea, etc., were thoroughlyevaluatedbyateamofphysician,otolaryngologist, ophthalmologist, neurosurgeon and, maxillofacial surgeon. HistoryofCOVID19infection,hospitalization,useofsteroid use/biologicals/higher antibiotics/oxygen, diabetes mellitus, hypertension,organtransplant,and so forth.Fmoc-D-Ser(tBu)-OH site ,wasrecorded.INDY Technical Information Allpatients underwentdeepnasalswabforKOHmountanddiagnostic nasal endoscopy (DNE) by otolaryngologist.PMID:36717102 We defined confirmed mucormycosis as these individuals obtaining clinically compatiblesignsandsymptomsanddemonstrationoffungi inthetissue(orbodyfluids)eitherbydirectmicroscopyand/or culture.[3] Individuals who were unfavorable on direct microscopy and DNE were treated as nonmucor sufferers by respective departments and were not incorporated within the study. Sufferers alsounderwentcomputerizedtomographyscanforparanasal sinuses (PNS) and magnetic resonance imaging (MRI) scan withcontrastfororbitandbraintoknowtheextentofdisease. On thebasisof involvement, individuals had been staged:Stage 1 oseandPNS;Stage2 ose,PNS,andorbit;Stage3 ose, PNS,orbit,andbrain.[4] Intravenous liposomal amphpotericin B (five mg/kg body weightforstage1,2and10mg/kgforstage3)wasgiventoall thepatientswithprovenmucormycosis.Systemiccomorbidities like diabetes and hypertension had been managed concurrently. Kidney function and serum electrolytes had been monitored each and every 48 hours. The individuals were subjected to radiological imagingtimetotimealongthecourseofinterventionand/or DNEtoknowthediseaseactivity.Repeatsinusand/orlocal tissue debridement was performed as and when needed. The resolutionwasconfirmedbyanegativesinusbiopsy.Liposomal amphoterecinBwascontinueduntil5daysofresolutionofthe illness,afterwhichoralposaconazolewasaddedinadoseof 5mg/kgbodyweight/day(BDonday1followedbyODfor 8weeksorlongerdependingonconditionofpatient). Stage 1: Patients had been managed by otolaryngologist by functionalendoscopicsinussurgery(F.